92 related articles for article (PubMed ID: 23422502)
21. Misclassification of incident conditions using claims data: impact of varying the period used to exclude pre-existing disease.
Griffiths RI; O'Malley CD; Herbert RJ; Danese MD
BMC Med Res Methodol; 2013 Mar; 13():32. PubMed ID: 23496890
[TBL] [Abstract][Full Text] [Related]
22. Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the medicare population.
Zlateva GP; Javitt JC; Shah SN; Zhou Z; Murphy JG
Retina; 2007; 27(9):1292-9. PubMed ID: 18046240
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of women with metachronous breast and ovarian carcinomas.
Liou WS; Hamilton CA; Cheung MK; Osann K; Longacre TA; Teng NN; Husain A; Dirbas FM; Chan JK
Gynecol Oncol; 2006 Oct; 103(1):190-4. PubMed ID: 16569424
[TBL] [Abstract][Full Text] [Related]
24. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome.
Anderson WF; Jatoi I; Devesa SS
Breast Cancer Res Treat; 2005 Mar; 90(2):127-37. PubMed ID: 15803359
[TBL] [Abstract][Full Text] [Related]
25. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
26. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients.
Alexander SL; Linde-Zwirble WT; Werther W; Depperschmidt EE; Wilson LJ; Palanki R; Saroj N; Butterworth SL; Ianchulev T
Ophthalmology; 2007 Dec; 114(12):2174-8. PubMed ID: 18054636
[TBL] [Abstract][Full Text] [Related]
27. Obtaining data on comorbid diabetes among patients in a U.S. population-based tumor registry.
Polednak AP; Phillips CE
J Registry Manag; 2010; 37(2):57-64. PubMed ID: 21086823
[TBL] [Abstract][Full Text] [Related]
28. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology of low-grade serous ovarian cancer.
Plaxe SC
Am J Obstet Gynecol; 2008 Apr; 198(4):459.e1-8; discussion 459.e8-9. PubMed ID: 18395040
[TBL] [Abstract][Full Text] [Related]
31. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data.
Lang K; Menzin J; Earle CC; Jacobson J; Hsu MA
Arch Otolaryngol Head Neck Surg; 2004 Nov; 130(11):1269-75. PubMed ID: 15545580
[TBL] [Abstract][Full Text] [Related]
32. A Retrospective Study of Comorbidities and Complications in Elderly Acute Myeloid Leukemia Patients in the United States.
Dhopeshwarkar N; Iqbal S; Wang X; Salas M
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e436-e456. PubMed ID: 31129110
[TBL] [Abstract][Full Text] [Related]
33. Temporal patterns of conditions and symptoms potentially associated with ovarian cancer.
Wynn ML; Chang S; Peipins LA
J Womens Health (Larchmt); 2007 Sep; 16(7):971-86. PubMed ID: 17903074
[TBL] [Abstract][Full Text] [Related]
34. Cancer and comorbidity in older patients: a descriptive profile.
Yancik R; Havlik RJ; Wesley MN; Ries L; Long S; Rossi WK; Edwards BK
Ann Epidemiol; 1996 Sep; 6(5):399-412. PubMed ID: 8915471
[TBL] [Abstract][Full Text] [Related]
35. Variation in chemotherapy utilization in ovarian cancer: the relative contribution of geography.
Polsky D; Armstrong KA; Randall TC; Ross RN; Even-Shoshan O; Rosenbaum PR; Silber JH
Health Serv Res; 2006 Dec; 41(6):2201-18. PubMed ID: 17116116
[TBL] [Abstract][Full Text] [Related]
36. Metabolic syndrome and risk of ovarian and fallopian tube cancer in the United States: An analysis of linked SEER-Medicare data.
Michels KA; McNeel TS; Trabert B
Gynecol Oncol; 2019 Nov; 155(2):294-300. PubMed ID: 31495456
[TBL] [Abstract][Full Text] [Related]
37. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality.
Yancik R
Cancer; 1993 Jan; 71(2 Suppl):517-23. PubMed ID: 8420671
[TBL] [Abstract][Full Text] [Related]
38. An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer.
Danese MD; O'Malley C; Lindquist K; Gleeson M; Griffiths RI
Ann Oncol; 2012 Jul; 23(7):1756-65. PubMed ID: 22039090
[TBL] [Abstract][Full Text] [Related]
39. Why have ovarian cancer mortality rates declined? Part II. Case-fatality.
Sopik V; Iqbal J; Rosen B; Narod SA
Gynecol Oncol; 2015 Sep; 138(3):750-6. PubMed ID: 26080288
[TBL] [Abstract][Full Text] [Related]
40. Cancer, comorbidities, and health-related quality of life of older adults.
Smith AW; Reeve BB; Bellizzi KM; Harlan LC; Klabunde CN; Amsellem M; Bierman AS; Hays RD
Health Care Financ Rev; 2008; 29(4):41-56. PubMed ID: 18773613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
